Mylan finalizes DoJ agreement, drawing line under EpiPen furore

17 August 2017

Netherlands-based Mylan (Nasdaq: MYL) has reached an agreement with the US Department of Justice, finalizing the previously announced Medicaid drug rebate settlement of $465 million.

The firm’s shares took a beating last year amid controversy, including a congressional hearing, over the classification of EpiPen (epinephrine) products as non-innovator drugs, which led to lower rebate payments to Medicaid.

Since first revealing the settlement, Mylan has posted upbeat financial guidance for the year. The near-half billion dollar payment was booked in the company’s 2016 accounts.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK